source
- Replimune secures FDA accelerated approval for melanoma therapy TudriqevReplimune announced that the FDA has granted accelerated approval to its melanoma therapy RP1, marketed as Tudriqev, after two earlier rejections and a third expedited review. The decision reflects…
- Latigo Biotherapeutics raises $345.6M in IPO to fund non-opioid pain drug pipelineLatigo Biotherapeutics, a Los Angeles-based biotech focused on non-opioid ion-channel-blocking pain therapies, completed an initial public offering on Thursday. The company sold 19.2 million share…